

FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB

PRESS RELEASE

Fraunhofer IGB joins international consortium to advance organ-on-a-chip technology in Europe

The consortium led by Leiden University Medical Center and the Dutch hDMT (human Disease Model Technologies) has been assigned by the EU with the task to create a roadmap for the future development of organ-on-chip technology. Its aim is to establish a European infrastructure to enable coordinated development, production and implementation of organ-on-a-chip systems. The consortium is funded by the EU FET-Open Program and brings together six leading European research institutions, including the Fraunhofer-Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart, Germany.

The consortium's aim is to accelerate the societal and economic impact of organ-on-achip technology through coordinated action. Organs-on-chips combine human miniorgans with microelectronics, microfluidics and nanosensors. This technology is already providing new platforms for drug discovery but is poised to deliver applications in personalized medicine and safety pharmacology, and offers alternatives to conventional animal testing. Over the next two years, the EU will invest 0.5 million Euros in the ORgan-on-CHip In Development (ORCHID) project.

ORCHID will facilitate dialogue and documentation towards accelerating the development of prototypes of organs-on-chips, validated cell systems that mimic diseased or healthy human tissue, and implementation of this technology by a broad group of potential users in science, health care and industry.

Within the consortium, the Fraunhofer IGB will focus on the economic and educational aspects of the ORCHID project. Dr. Peter Loskill, head of the institute's research group on organ-on-a-chip systems, and his team will evaluate which skills are essential for the development and application of organ-on-a-chip technology. On this basis, it is possible to identify specific training contents for the further education of researchers, developers, and users. A further task of Dr. Loskill and his team will be the assessment of suitable business models for the commercialization of organ-on-a-chip systems, taking advantage of the extensive economic expertise of the Fraunhofer IGB as an application-oriented research institute.

Ultimately, ORCHID will build an infrastructure for scientists, policy makers, funders and end-users to join the decision-making processes that will direct future European developments in organ-on-a-chip applications. An essential contribution of ORCHID will be the establishment of a digital platform enabling knowledge sharing between researchers and representatives of private corporations including insurance companies, pharmaceutical and biotech companies, food industry, health foundations and patient organizations.

PRESS RELEASE October 30, 2017 || Page 1 | 3



FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB

The ORCHID platform will provide overviews and updates of current and new organon-a-chip initiatives so that users can track progress easily, consult developers directly and identify gaps in present knowledge, limiting implementation. ORCHID will also address ethical and regulatory issues, particularly concerning personalized information, economic and societal impact, training of researchers, and the design of an R&D roadmap.

The consortium is composed of the following organizations:


- Leiden University Medical Center, the Netherlands; coordinator contact: Christine Mummery, PhD, Professor of Developmental Biology, Chair Dept. of Anatomy
- Organ-on-Chip consortium hDMT, the Netherlands; strategy and the roadmap contact: Janny van den Eijnden van Raaij, PhD, Managing director
- Fraunhofer IGB, Germany; Peter Loskill, PhD, Attract Group Manager Organon-a-chip, Department of Cell and Tissue Engineering
- CEA LETI, France; eco-system development and the digital platform contact: Adrienne Pervès PhD, Deputy Head of Department-LETI-Technologies for biology and health
- Imec, Belgium; ethical aspects, regulation and standardization contact: Wolfgang Eberle, PhD, Funded Program Manager Smart Health and NERF Coordinator EIT Health
- University of Zaragoza, Spain; dissemination contact: Luis Fernandez, PhD, Professor Mechanical Engineering, Dept. of Applied Mechanics and Bioengineering

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 766884

PRESS RELEASE October 30, 2017 || Page 2 | 3



FRAUNHOFER INSTITUTE FOR INTERFACIAL ENGINEERING AND BIOTECHNOLOGY IGB



PRESS RELEASE October 30, 2017 || Page 3 | 3

Microphysiological Organ-on-achip system. (© Fraunhofer IGB) | Picture in color and printing quality: www.igb.fraunhofer.de/press

Reprints free of charge. A voucher copy is appreciated in case of publication.

Contact Scientific Department

Dr. Peter Loskill | Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB | Nobelstrasse 12 | 70569 Stuttgart | Germany | www.igb.fraunhofer.de | Phone +49 711 970-3531 | peter.loskill@igb.fraunhofer.de

Contact Press

Dr. Claudia Vorbeck | Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB | Nobelstrasse 12 | 70569 Stuttgart | Germany | www.igb.fraunhofer.de | Phone +49 711 970-4031 | claudia.vorbeck@igb.fraunhofer.de

The **Fraunhofer-Gesellschaft** is the leading organization for applied research in Europe. Its research activities are conducted by 67 institutes and research units at locations throughout Germany. The Fraunhofer-Gesellschaft employs a staff of 24,000, who work with an annual research budget totaling more than 2.1 billion euros. Of this sum, more than 1.8 billion euros is generated through contract research. More than 70 percent of the Fraunhofer-Gesellschaft's contract research revenue is derived from contracts with industry and from publicly financed research projects. International collaborations with excellent research partners and innovative companies around the world ensure direct access to regions of the greatest importance to present and future scientific progress and economic development.

The **Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB** develops and optimizes processes and products in the fields of health, chemistry and process industry, as well as environment and energy. We combine the highest scientific standards with professional know-how in our competence areas – always with a view to economic efficiency and sustainability. Our strengths are offering complete solutions from the laboratory to the pilot scale. Customers also benefit from the cooperation between our five R&D departments in Stuttgart and the institute branches located in Leuna, Straubing and Würzburg. The constructive interplay of the various disciplines at our institute opens up new approaches in areas such as medical engineering, nanotechnology, industrial biotechnology, and environmental technology.